A targeted treatment for men with PSMA+ mCRPC

What is the most important information I should know about PLUVICTO?


Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased ris...

See More
What is PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen­–­positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that:...

See More

mCRPC, metastatic castration-resistant prostate cancer; PSMA+, prostate-specific membrane antigen positive.